ENSC VS NEXI Stock Comparison

Performance

ENSC
10/100

ENSC returned -96.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

NEXI
10/100

NEXI returned -75.26% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

ENSC
25/100

ENSC receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

NEXI
25/100

NEXI receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

Earnings

ENSC
33/100

ENSC has missed earnings 3 times in the last 20 quarters.

NEXI
49/100

NEXI has missed earnings 2 times in the last 20 quarters.

Profit

ENSC
27/100

Out of the last 20 quarters, ENSC has had 8 profitable quarters and has increased their profits year over year on 2 of them.

NEXI
10/100

Out of the last 15 quarters, NEXI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ENSC
50/100

ENSC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

NEXI
38/100

NEXI has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Ensysce Biosciences, Inc. Common Stock Summary

Nasdaq / ENSC

Healthcare

Biotechnology

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

NexImmune, Inc. Common Stock Summary

Nasdaq / NEXI

Healthcare

Biotechnology

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Power up your portfolio